Quality of your (Social) Life

Many metrics purport to measure individuals quality of life.  Tools such as the EQ-5D and SF-36 do so largely based on functional status.  Using other surveys on individual preferences, one can estimate patient utility for any given functional status level (i.e,. EQ-5D or SF-36 score).  What these scores ignore, however, is the social component of…

Are multiple sclerosis treatments worth the cost? Comparing how treatment “value” is determined by five cost effectiveness analyses

by Daniel Kantor, Michelle Brauer and Jason Shafrin As drug prices continue to rise, many patients, payers and policymakers are asking whether the treatment benefits justify the cost. One method favored by health technology assessment (HTA) bodies for making this decision in a formal manner is to conduct a cost effectiveness analyses (CEA).  However, there…

Patient and Physician Risk Preferences

Physicians are supposed to act as agents for patients, acting in their best interest. But a question is, how well do physician know patient preferences? How well do physician preferences reflect those of patients. Previous research indicates that for terminal diseases, patients are risk loving. My own recently published research (with co-authors Schwartz, Okoro and…

ISPOR Paper of the year

The ISPOR paper of the year award for best publication in Value in Health was given to Basch et al. (2016) for their study titled Methods for Developing Patient-Reported Outcome-Based Performance Measures (PRO-PMs).  The abstract is below. Objective: To recommend methods for assessing quality of care via patient-reported outcome-based performance measures (PRO-PMs) of symptoms, functional status,…